Skip to main content

Advertisement

Table 1 Patient and tumor characteristics

From: A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study

Characteristics Arm A(EV) = 54 Arm B(PLD/V) = 50
  No. % No. %
Age, years   
   Median 63 61
   Range 27-70 35-69
Pre/Postmenopausal 10/44 9/41
Median ECOGPS (range) 1(0-3) 1(0-3)
*HR status     
   Positive 39 72.2 32 64.0
   Negative 13 24.1 15 30.0
   Unknown 2 3.7 3 6.0
HER-2 status     
   Positive     
   Negative     
   Unknown     
Prior adjuvant chemotherapy** 20 37 21 42
Prior hormonal therapy     
   Adjuvant 35 64.8 30 60
   Advanced 10 18.5 11 22
Disease free-interval (years)     
   < 1 10   11  
   1-5 30   28  
   >5 14   11  
Dominant disease site     
   Viscera 40 74.0 32 64.0
   Bone 11 20.4 9 18.0
   Soft tissue 3 5.6 9 18.0
Number of disease site     
   1 23 42.6 23 46.0
   2 23 42.6 18 36.0
   ≥ 3 8 42.6 9 18.0
  1. * HR: hormonal receptor status
  2. ** not including anthracyclines or vinka alkaloids
  3. EV: epirubicin/vinorelbine; PLD/V: pegylated liposomal doxorubicin/vinorelbine